Search results
Showing 8221 to 8235 of 8973 results
Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]
Discontinued Reference number: GID-TA10228
Discontinued Reference number: GID-TA10318
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
Discontinued Reference number: GID-TA10363
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued Reference number: GID-TA10295
Discontinued Reference number: GID-TA10196
Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]
Discontinued Reference number: GID-TA10158
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
In development Reference number: GID-TA10899 Expected publication date: TBC
Inotersen for treating hereditary transthyretin amyloidosis (HST9)
NICE has withdrawn this guidance. Sobi will stop marketing inotersen (Tegsedi) because its no longer available in the UK. Healthcare professionals should discuss alternative treatment options with people currently having inotersen.
In development Reference number: GID-TA11299 Expected publication date: TBC
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
Discontinued Reference number: GID-TA10597
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Discontinued Reference number: GID-TA10596
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development Reference number: GID-TA10555 Expected publication date: TBC
In development Reference number: GID-TA11655 Expected publication date: TBC
Discontinued Reference number: GID-TA11001
In development Reference number: GID-TA11800 Expected publication date: TBC